gene

RGS6

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about RGS6: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

74Connections

9Hypotheses

3Analyses

50Outgoing

9Incoming

0Experiments

3Debates

Summary

Page for RGS6 Gene

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	RGS6
Chromosome	14q24.2
Function	is an important component in the neurobiology of neurodegenerative diseases.
Primary Expression	Cerebellum, Hippocampus, Retina
Molecular Weight	56 kDa
Pathways	oxidative stress response
UniProt ID	Q9Y5Z4
NCBI Gene ID	9628
Ensembl ID	ENSG00000111664
OMIM	603894
GeneCards	RGS6
Human Protein Atlas	RGS6
Associated Diseases	neurodegeneration, Parkinson's disease
Known Drugs/Compounds	levodopa
Interactions	AND, NEURON, PARKINSON, Α-Synuclein
SciDEX Hypotheses	AAV-mediated RGS6 re-expression in SNpc after path TH-neuron-restricted RGS6 rescue to test cell-auto Combination RGS6 restoration plus D2-pathway modul (+1 more)
KG Connections	74 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: RGS6 — AlphaFold Q9Y5Z4 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (2)

Knowledge base pages for this entity

Canonical Page

RGS6 Gene

gene · 872 words

→

RGS6 Protein

protein · 611 words

→

Pathway Diagram

graph TD
    RGS6["RGS6"]
    Neurodegeneration{"Neurodegeneration"}
    RGS6 -->|"regulates"| Neurodegeneration
    Parkinson{"Parkinson"}
    RGS6 -->|"expressed in"| Parkinson
    Camp_Signaling(["Camp Signaling"])
    RGS6 -->|"inhibits"| Camp_Signaling
    PARKINSON["PARKINSON"]
    RGS6 -->|"expressed in"| PARKINSON
    NEURODEGENERATION["NEURODEGENERATION"]
    RGS6 -->|"regulates"| NEURODEGENERATION
    Substantia_Nigra["Substantia Nigra"]
    RGS6 -->|"expressed in"| Substantia_Nigra
    Neuron["Neuron"]
    RGS6 -->|"expressed in"| Neuron
    neurodegeneration["neurodegeneration"]
    RGS6 -->|"implicated in"| neurodegeneration
    NEURON["NEURON"]
    NEURON -->|"inhibits"| RGS6
    AND["AND"]
    AND -->|"inhibits"| RGS6
    style RGS6 fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (65)

Target	Relation	Type	Str
Substantia Nigra Pars Compacta	expressed_in	cell_type	0.95
Parkinson'S Disease	protects_against	disease	0.95
dopamine neuron degeneration	protects_against	process	0.95
Gi/o Signaling	inhibits	pathway	0.95
Gi/O Signaling	inhibits	pathway	0.95
Substantia Nigra Pars Compacta Dopamine Neurons	expressed_in	cell_type	0.90
D2 Autoreceptor Signaling	suppresses	pathway	0.90
D2 AUTORECEPTOR	associated_with	receptor	0.90
α-synuclein Accumulation	protects_against	phenotype	0.90
DRD2	modulates	gene	0.90
dopaminergic neurodegeneration	causes	process	0.90
α-synuclein accumulation	causes	process	0.90
cAMP signaling	upregulates	pathway	0.90
Dopamine Neuron Survival	protects_against	process	0.88
SNCA	downregulates	gene	0.85
Camp	regulates	compound	0.85
Dopaminergic Neurodegeneration	protects_against	process	0.85
nigrostriatal dopamine	mediates	phenotype	0.85
motor deficits	suppresses	phenotype	0.85
Parkinson	expressed_in	disease	0.65
Neurodegeneration	regulates	disease	0.65
AND	inhibits	gene	0.60
neurodegeneration	associated_with	disease	0.60
neurodegeneration	regulates	disease	0.60
Dopaminergic	associated_with	cell_type	0.60
Neuron	inhibits	cell_type	0.60
Α-Synuclein	inhibits	protein	0.60
Parkinson's disease	regulates	disease	0.60
PARKINSON	expressed_in	gene	0.60
NEURODEGENERATION	regulates	gene	0.60
oxidative stress response	participates_in	pathway	0.60
striatum	expressed_in	brain_region	0.60
neurons	expressed_in	cell_type	0.60
Parkinson's disease	expressed_in	disease	0.60
Parkinson's disease	associated_with	disease	0.60
Camp Signaling	inhibits	pathway	0.60
Substantia Nigra	expressed_in	brain_region	0.55
Neuron	expressed_in	cell_type	0.55
α-SYNUCLEIN	associated_with	concept	0.50
SYNUCLEIN	associated_with	concept	0.50
DOPAMINERGIC	associated_with	concept	0.50
DOPAMINE	associated_with	concept	0.50
SYNUCLEIN	activates	concept	0.50
DOPAMINE	activates	concept	0.50
α-SYNUCLEIN	activates	concept	0.50
SYNUCLEIN	inhibits	concept	0.50
DOPAMINE	inhibits	concept	0.50
α-SYNUCLEIN	inhibits	concept	0.50
NEURONS	expressed_in	concept	0.50
PARKINSON'S	expressed_in	concept	0.50

Incoming (9)

Source	Relation	Type	Str
levodopa	targets	drug	0.60
NEURON	inhibits	gene	0.60
LATE	inhibits	disease	0.60
NEURODEGENERATION	associated_with	entity	0.60
NEURODEGENERATION	regulates	entity	0.60
PARKINSON	expressed_in	gene	0.60
Neurodegeneration	regulates	disease	0.50
Neurodegeneration	associated_with	disease	0.50
late	inhibits	disease	0.50

Targeting Hypotheses (9)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
AAV-mediated RGS6 re-expression in SNpc after pathology onse	0.530	neurodegeneration	Does RGS6 upregulation or D2 autorecepto
NRF2 Activation to Counteract Oxidative Stress from RGS6 Def	0.518	neurodegeneration	Does RGS6 upregulation or D2 autorecepto
TH-neuron-restricted RGS6 rescue to test cell-autonomous the	0.480	neurodegeneration	Does RGS6 upregulation or D2 autorecepto
AAV-Mediated RGS6 Overexpression in Substantia Nigra Parvoce	0.424	neurodegeneration	Does RGS6 upregulation or D2 autorecepto
D2 Autoreceptor Partial Agonism as Compensatory Therapy for	0.348	neurodegeneration	Does RGS6 upregulation or D2 autorecepto

Combination Gene Therapy Targeting RGS6 and Parkin or PINK1	0.317	neurodegeneration	Does RGS6 upregulation or D2 autorecepto
Combination RGS6 restoration plus D2-pathway modulation	0.310	neurodegeneration	Does RGS6 upregulation or D2 autorecepto
PDE10A Inhibition to Bypass RGS6 Deficiency via cAMP Pathway	0.224	neurodegeneration	Does RGS6 upregulation or D2 autorecepto
RGS6 isoform switching or small-molecule RGS6 activation as	0.220	neurodegeneration	Does RGS6 upregulation or D2 autorecepto

Mentioning Analyses (3)

Scientific analyses that reference this entity

Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration i

neurodegeneration | 2026-04-25 | 5 hypotheses Top: 0.530

Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration i

neurodegeneration | 2026-04-17 | 7 hypotheses Top: 0.559

Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration i

neurodegeneration | 2026-04-16 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (3)

Multi-agent debates referencing this entity

Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration i

closed · Rounds: 4 · Score: 0.54 · 2026-04-25

While RGS6 deficiency causes Parkinson's-like pathology, whether enhancing RGS6

closed · Rounds: 4 · Score: 0.50 · 2026-04-18

While RGS6 deficiency causes Parkinson's-like pathology, whether enhancing RGS6

closed · Rounds: 4 · Score: 0.50 · 2026-04-18

Related Research

Hypotheses and analyses mentioning RGS6 in their description or question text

Combination Gene Therapy Targeting RGS6 and Parkin or PINK1 to Address Mitochond

Score: 0.317 · neurodegeneration · 2026-04-18

## Mechanistic Overview Combination Gene Therapy Targeting RGS6 and Parkin or PINK1 to Address Mitochondrial Dysfunction

Combination RGS6 restoration plus D2-pathway modulation

Score: 0.310 · neurodegeneration · 2026-04-25

Combine subthreshold RGS6 rescue with D2-pathway modulation to test whether benefit requires convergent normalization of

PDE10A Inhibition to Bypass RGS6 Deficiency via cAMP Pathway Normalization

Score: 0.224 · neurodegeneration · 2026-04-18

## Mechanistic Overview PDE10A Inhibition to Bypass RGS6 Deficiency via cAMP Pathway Normalization starts from the claim

RGS6 isoform switching or small-molecule RGS6 activation as disease-modifying th

Score: 0.220 · neurodegeneration · 2026-04-25

Pursue either isoform-specific RGS6 engineering or pharmacologic RGS6 activation to enhance protective signaling. The de